Table 2.
Pharmacokinetic parameters of PUE following oral administration of AP formulations (mean ± SD, n=6)
| Parameter | AP suspension | AP-PLGA-NPs |
|---|---|---|
| AUC0–∞ (h ng/mL) | 2,243.08±520.36 | 6,175.66±350.31* |
| MRT0–∞ (h) | 2.81±0.17 | 5.01±0.23* |
| t1/2 (h) | 1.41±0.21 | 3.07±0.18* |
| Tmax (h) | 1.83±0.29 | 1.13±0.31* |
| CL (L/h/kg) | 13.80±2.79 | 4.87±0.28* |
| Cmax (ng/mL) | 731.83±95.79 | 1,301.13±101.41* |
Notes:
*
P<0.01 vs AP suspension. Statistical significances were determined as follows: MRT, t1/2, and CL: one-way ANOVA; AUC and Cmax: one-way ANOVA following logarithmic transformation; Tmax: Mann–Whitney U-test.
Abbreviations: ANOVA, analysis of variance; AP, acetylpuerarin; PLGA, poly(lactide-co-glycolide); NPs, nanoparticles; AUC0–∞, area under the plasma concentration-time curve; MRT0–∞, mean residence time; PUE, puerarin; t1/2, elimination half-life; Tmax, time to maximum concentration; CL, plasma clearance; Cmax, maximum plasma concentration; SD, standard deviation.